As predictive markers for the treatment choices are not available, the recommendations for systemic therapies are based on the proliferative capacity of the disease (measured in Ki-67), the extent of metastasis, tumor-related symptoms, functionality, and patient-specific comorbidities [10]. Here, MKI67 is linked to neoplasm.